The Drugs Controller General of India (DCGI) on Sunday (July 4, 2021) granted a licence to Panacea Biotec for manufacturing the Russian COVID-19 vaccine, Sputnik V, in India.
Sputnik V has been registered in 54 countries globally with a total population of over 1.4 billion people. The efficacy of Sputnik V is 91.6 percent as confirmed by the data published in the Lancet.
The pharma company tied up with Russian Direct Investment Fund (RDIF) to produce the COVID-19 vaccine in the country. The Russian vaccine, Sputnik V, has been part of India’s fight against COVID-19 since 14 May.
Batches of the vaccine produced at its facilities in Baddi, Himachal Pradesh, were shipped earlier to the Gamaleya Center in Russia for quality control. The batches “successfully passed all the checks for quality parameters both at the Gamaleya Center and at the Central Drug Laboratory, Kasauli, Himachal Pradesh,” the company said on Sunday.